APEIRON Biologics AG
APEIRON Biologics AG's Overview
Apeiron Biologics AG is a privately-owned European biotechnology company based in Vienna, Austria, focused on the discovery, development, and commercialization of novel immunotherapies for cancer and treatments for respiratory diseases. The company leverages its expertise in immunology and biologicals to develop innovative treatments. Key projects include APN401, an autologous cell therapy targeting the Cbl-b immune checkpoint for solid tumors, and their previously approved product Qarziba® (dinutuximab beta) for neuroblastoma (rights sold to EUSA Pharma). They also gained attention for APN01 (alunacedase alfa), a recombinant human angiotensin-converting enzyme 2 (rhACE2), investigated for COVID-19 treatment.
Where is APEIRON Biologics AG's Headquarters?
HQ Function
The Vienna headquarters serves as the central hub for Apeiron Biologics' research and development, clinical operations, corporate strategy, business development, and administrative functions.
Notable Features:
Located within the Vienna BioCenter, one of Europe's leading life science research and education centers, providing access to state-of-the-art infrastructure, a collaborative scientific community, and a rich talent pool.
Work Culture:
Apeiron Biologics fosters a dynamic, innovative, and science-driven work culture. Emphasis is placed on collaboration, cutting-edge research, and a commitment to developing therapies for patients with high unmet medical needs.
HQ Significance:
The strategic location in Vienna BioCenter facilitates collaborations with academic institutions and other biotech companies, and supports its R&D efforts in the competitive field of immuno-oncology.
Values Reflected in HQ: The headquarters' location and setup reflect Apeiron's commitment to scientific excellence, innovation, collaboration, and its focus on translating research into tangible therapeutic solutions.
Location:
While headquartered in Vienna, Austria, Apeiron Biologics operates with a global perspective. Its clinical trials often involve multiple international sites, and it seeks partnerships and collaborations worldwide to advance its therapeutic programs. The company aims for its products, once approved, to reach patients globally, particularly in major pharmaceutical markets like Europe and North America, and has explored partnerships for specific regions like China.
Street Address:
Campus-Vienna-BioCenter 5
City:
Vienna
State/Province:
Vienna
Country:
Austria
APEIRON Biologics AG's Global Presence
Buying Intent Signals for APEIRON Biologics AG
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of APEIRON Biologics AG
As of April 2025, APEIRON Biologics AG' leadership includes:
Investors of APEIRON Biologics AG
APEIRON Biologics AG has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
No major publicly announced executive hires or departures have been identified for Apeiron Biologics in the immediate last 12 months. The current leadership team appears to have been stable.
Technology (Tech Stack) used by APEIRON Biologics AG
Discover the tools APEIRON Biologics AG uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
APEIRON Biologics AG Email Formats and Examples
Common email formats for Apeiron Biologics likely follow standard corporate patterns such as [first_initial][last]@[domain] or [first].[last]@[domain]. The specific format can sometimes be confirmed via LinkedIn or by contacting the company directly.
pllewellyn-davies@apeiron-biologics.com (based on [first_initial][last_name] format)
Format
j.doe@apeiron-biologics.com
Example
75%
Success rate
News and media
Business Wire • April 9, 2024
Apeiron Biologics Presents Positive Preclinical Data for its Novel Immuno-Oncology Therapy APN401 (SIRPα-CD47 Blockade) at AACR 2024
Apeiron Biologics AG announced the presentation of compelling preclinical data for APN401, its clinical stage anti-SIRPα antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2024. The data highlight APN401's potential as a potent immuno-oncology agent through its unique mechanism of targeting the SIRPα-CD47 checkpoint....more
Apeiron Biologics Press Release • November 7, 2023
Apeiron Biologics Receives Further Grant Funding from FFG to Advance its Lead Immuno-Oncology Candidate APN401
Apeiron Biologics announced it has secured additional grant funding from the Austrian Research Promotion Agency (FFG) for the development of its lead immuno-oncology candidate, APN401. This funding will support the ongoing clinical development of APN401, an autologous cell therapy targeting the intracellular immune checkpoint Cbl-b....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including APEIRON Biologics AG, are just a search away.